Swiss National Bank’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.76M | Buy |
112,200
+900
| +0.8% | +$87.5K | 0.01% | 970 |
|
|
2025
Q4 | $11.9M | Buy |
111,300
+9,000
| +9% | +$955K | 0.01% | 873 |
|
|
2025
Q3 | $10.3M | Buy |
102,300
+11,700
| +13% | +$1.09M | 0.01% | 949 |
|
|
2025
Q2 | $5.73M | Buy |
90,600
+1,300
| +1% | +$79.6K | ﹤0.01% | 1212 |
|
|
2025
Q1 | $4.73M | Sell |
89,300
-900
| -1% | -$49.9K | ﹤0.01% | 1293 |
|
|
2024
Q4 | $5.05M | Buy |
90,200
+900
| +1% | +$49.7K | ﹤0.01% | 1328 |
|
|
2024
Q3 | $4.68M | Buy |
89,300
+600
| +0.7% | +$28.8K | ﹤0.01% | 1366 |
|
|
2024
Q2 | $3.64M | Sell |
88,700
-4,600
| -5% | -$184K | ﹤0.01% | 1465 |
|
|
2024
Q1 | $4.04M | Buy |
93,300
+3,600
| +4% | +$158K | ﹤0.01% | 1422 |
|
|
2023
Q4 | $4.12M | Sell |
89,700
-10,200
| -10% | -$322K | ﹤0.01% | 1407 |
|
|
2023
Q3 | $2.29M | Buy |
99,900
+1,100
| +1% | +$24.6K | ﹤0.01% | 1746 |
|
|
2023
Q2 | $1.63M | Buy |
98,800
+1,500
| +2% | +$27.1K | ﹤0.01% | 2026 |
|
|
2023
Q1 | $1.74M | Sell |
97,300
-600
| -0.6% | -$15.1K | ﹤0.01% | 1925 |
|
|
2022
Q4 | $2.85M | Buy |
97,900
+8,300
| +9% | +$213K | ﹤0.01% | 1656 |
|
|
2022
Q3 | $2.19M | Buy |
89,600
+6,300
| +8% | +$117K | ﹤0.01% | 1809 |
|
|
2022
Q2 | $346K | Hold |
83,300
| – | – | ﹤0.01% | 2694 |
|
|
2022
Q1 | $960K | Buy |
83,300
+5,600
| +7% | +$49.1K | ﹤0.01% | 2429 |
|
|
2021
Q4 | $775K | Hold |
77,700
| – | – | ﹤0.01% | 2560 |
|
|
2021
Q3 | $1.01M | Buy |
77,700
+1,700
| +2% | +$26K | ﹤0.01% | 2430 |
|
|
2021
Q2 | $1.49M | Sell |
76,000
-2,700
| -3% | -$56.1K | ﹤0.01% | 2285 |
|
|
2021
Q1 | $1.67M | Buy |
78,700
+23,700
| +43% | +$687K | ﹤0.01% | 2110 |
|
|
2020
Q4 | $1.64M | Hold |
55,000
| – | – | ﹤0.01% | 2024 |
|
|
2020
Q3 | $1.19M | Buy |
55,000
+1,000
| +2% | +$22.9K | ﹤0.01% | 1997 |
|
|
2020
Q2 | $1.2M | Sell |
54,000
-5,600
| -9% | -$109K | ﹤0.01% | 1999 |
|
|
2020
Q1 | $907K | Buy |
59,600
+2,500
| +4% | +$44.8K | ﹤0.01% | 1884 |
|
|
2019
Q4 | $1.31M | Buy |
57,100
+21,900
| +62% | +$487K | ﹤0.01% | 1983 |
|
|
2019
Q3 | $760K | Hold |
35,200
| – | – | ﹤0.01% | 2198 |
|
|
2019
Q2 | $774K | Buy |
35,200
+3,900
| +12% | +$98.5K | ﹤0.01% | 2252 |
|
|
2019
Q1 | $858K | Buy |
31,300
+1,100
| +4% | +$31.6K | ﹤0.01% | 2148 |
|
|
2018
Q4 | $812K | Buy |
30,200
+1,600
| +6% | +$44.2K | ﹤0.01% | 2121 |
|
|
2018
Q3 | $834K | Hold |
28,600
| – | – | ﹤0.01% | 2243 |
|
|
2018
Q2 | $894K | Buy |
+28,600
| New | +$782K | ﹤0.01% | 2237 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Swiss National Bank's RYTM Position: Q1 2026 in Review
Swiss National Bank increased its Rhythm Pharmaceuticals (RYTM) stake by 0.81% in Q1 2026, buying an estimated $87.5K and bringing the position to 112,200 shares worth $9.76M. The position accounts for 0.01% of the portfolio, ranked #970.
Swiss National Bank first reported a position in RYTM in Q2 2018 and has held it in 32 quarters since. The position peaked at $11.9M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Swiss National Bank held 112,200 shares of Rhythm Pharmaceuticals worth $9.76M as of Q1 2026.
- Swiss National Bank bought 900 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $87.5K.
- Rhythm Pharmaceuticals made up 0.01% of Swiss National Bank's portfolio in Q1 2026, its #970 holding.
- Swiss National Bank first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- Swiss National Bank's Rhythm Pharmaceuticals position peaked at $11.9M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.